Akebia Therapeutics

Update in progress

AKBA (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Akebia Therapeutics is a biopharma company focused on kidney disease treatments. Its products include Vafseo (vadadustat), an oral HIF prolyl hydroxylase inhibitor for anemia in CKD patients on dialysis and not on dialysis; and Auryxia (ferric citrate) to control serum phosphorus in dialysis-dependent CKD and treat iron deficiency anemia in non-dialysis CKD. It also develops AKB-9090 for cardiac surgery–related AKI and ARDS, and AKB-10108 for retinopathy of prematurity. The company is based in Cambridge, MA, founded in 2007.

Company score

Sentiment: 0.32; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive